

Somaxon Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today announced that Richard Pascoe, president and chief executive officer, will present a company overview at the 11th Annual BIO CEO & Investor Conference at the Waldorf-Astoria in New York City on Monday, February 9, 2009, at 12:45 p.m. PT (3:45 p.m. ET).
A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at [ www.somaxon.com ]. The webcast will be archived and accessible for at least 14 days.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. A New Drug Application (NDA) for Silenor® (doxepin), Somaxon's drug candidate for insomnia, has been filed with the U.S. Food and Drug Administration and currently is under review.
For more information, please visit the company's web site at [ www.somaxon.com ].